Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingfei Jianpi desensitization prescription is a Traditional Chinese Medicine (TCM) herbal formula developed by Beijing Tongren Hospital, Capital Medical University, for the early intervention and prevention of seasonal allergic rhinitis (SAR). The prescription is designed to be administered starting before the onset of the pollen season and continuing through it to mitigate allergic symptoms and improve quality of life. Its therapeutic approach is based on the TCM principles of "clearing the lung" (Qingfei) and "strengthening the spleen" (Jianpi), which are intended to address the underlying constitutional imbalances associated with allergic conditions. Clinical evaluation of the formula, such as in trial ChiCTR2200060198, focuses on its efficacy in reducing symptom scores and modulating immune factors within nasal secretions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qingfei jianpi desensitization prescription.